{"success":true,"data":{"pressRelease":{"id":"3295","rtpr_id":"nNFC9J0Xg9","ticker":"SLNO","exchange":"NASDAQ","all_tickers":["SLNO"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","published_at":"2026-04-21T16:00:13.984Z","article_body":"New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Soleno Therapeutics, Inc.\n(NASDAQ: SLNO) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Soleno securities between March\n26, 2025 and November 4, 2025, both dates inclusive (the \"Class Period\"). Such\ninvestors are encouraged to join this case by visiting the firm's site:\nbgandg.com/SLNO (https://api.newsfilecorp.com/redirect/ppwYYs5K0r).\n\nSoleno Case Details\n\nThe Complaint alleges that throughout the Class Period, Defendants failed to\ndisclose that: (1) the Soleno Phase 3 clinical trial program for DCCR had\nsystematically downplayed, misrepresented, and/or concealed significant\nevidence of safety concerns potentially related to the administration of DCCR,\nincluding issues related to excess fluid retention in clinical trial\nparticipants; (2) as a result, the administration of DCCR to treat hyperphagia\nin individuals with PWS posed materially greater safety risks than disclosed\nby Soleno or its executives; and (3) consequently, DCCR had materially lower\ncommercial viability and undisclosed risks related to the likelihood of\nsignificant and widespread adverse events after its commercial launch,\nincluding risks related to patient discontinuation rates, lower patient\nadoption, prescriber reluctance, adverse regulatory action, and potential\nreputational and legal fallout.\n\nWhat's Next for Soleno Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/SLNO\n(https://api.newsfilecorp.com/redirect/YEK33FMK1n), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Soleno you\nhave until May 5, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Soleno Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Soleno Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/RYKppFOvxr), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/WAEVVuM2AA), X\n(https://api.newsfilecorp.com/redirect/qpwNNsKNWn), Facebook\n(https://api.newsfilecorp.com/redirect/noE22SMx3e), or Instagram\n(https://api.newsfilecorp.com/redirect/KLkppHJBrg).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/293011","article_body_html":"","raw_payload":{"data":{"id":"nNFC9J0Xg9","title":"Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","ticker":"SLNO","created":"2026-04-21T16:00:13.984Z","tickers":["SLNO"],"exchange":"NASDAQ","article_body":"New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Soleno Therapeutics, Inc.\n(NASDAQ: SLNO) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Soleno securities between March\n26, 2025 and November 4, 2025, both dates inclusive (the \"Class Period\"). Such\ninvestors are encouraged to join this case by visiting the firm's site:\nbgandg.com/SLNO (https://api.newsfilecorp.com/redirect/ppwYYs5K0r).\n\nSoleno Case Details\n\nThe Complaint alleges that throughout the Class Period, Defendants failed to\ndisclose that: (1) the Soleno Phase 3 clinical trial program for DCCR had\nsystematically downplayed, misrepresented, and/or concealed significant\nevidence of safety concerns potentially related to the administration of DCCR,\nincluding issues related to excess fluid retention in clinical trial\nparticipants; (2) as a result, the administration of DCCR to treat hyperphagia\nin individuals with PWS posed materially greater safety risks than disclosed\nby Soleno or its executives; and (3) consequently, DCCR had materially lower\ncommercial viability and undisclosed risks related to the likelihood of\nsignificant and widespread adverse events after its commercial launch,\nincluding risks related to patient discontinuation rates, lower patient\nadoption, prescriber reluctance, adverse regulatory action, and potential\nreputational and legal fallout.\n\nWhat's Next for Soleno Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/SLNO\n(https://api.newsfilecorp.com/redirect/YEK33FMK1n), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Soleno you\nhave until May 5, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Soleno Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Soleno Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/RYKppFOvxr), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/WAEVVuM2AA), X\n(https://api.newsfilecorp.com/redirect/qpwNNsKNWn), Facebook\n(https://api.newsfilecorp.com/redirect/noE22SMx3e), or Instagram\n(https://api.newsfilecorp.com/redirect/KLkppHJBrg).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/293011"},"type":"article","timestamp":"2026-04-21T16:00:14.029064422Z","server_sent_at_ms":1776787214029},"received_at":"2026-04-21T16:00:14.084Z","source_url":"https://www.newsfilecorp.com/release/293011"},"analysis":{"id":"2199","press_release_id":"3295","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Allegations of concealing significant safety concerns (excess fluid retention) in Phase 3 DCCR trial","Lawsuit claims lead drug has materially lower commercial viability than disclosed","Securities fraud class action filed covering majority of 2025"],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC announced a class action lawsuit against Soleno Therapeutics alleging violations of federal securities laws related to the company's Phase 3 clinical trial program for DCCR.\n\nThe complaint claims Soleno failed to disclose significant evidence of safety concerns, specifically excess fluid retention, which allegedly poses greater safety risks and lowers the commercial viability of DCCR for treating Prader-Willi Syndrome (PWS).\n\nInvestors who purchased Soleno securities between March 26, 2025, and November 4, 2025, have until May 5, 2026, to seek appointment as lead plaintiff.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Securities fraud suit alleges Soleno hid safety risks in Phase 3 DCCR trial, casting doubt on the drug's commercial outlook."},"keyFigures":{"drugName":"DCCR","phaseOfTrial":"Phase 3","customDimensions":{"class_period_end":"November 4, 2025","class_period_start":"March 26, 2025","lead_plaintiff_deadline":"May 5, 2026"}},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["DCCR"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO","relationship":"defendant"},{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"A class action lawsuit alleging securities fraud regarding the lead asset DCCR poses significant legal and reputational risk, specifically challenging the disclosure of safety data and commercial viability."},"tickerRelevance":{"others":[],"primary":"SLNO"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"Bronstein, Gewirtz & Grossman, LLC announced a class action lawsuit against Soleno Therapeutics alleging violations of federal securities laws related to the company's Phase 3 clinical trial program for DCCR.\n\nThe complaint claims Soleno failed to disclose significant evidence of safety concerns, specifically excess fluid retention, which allegedly poses greater safety risks and lowers the commercial viability of DCCR for treating Prader-Willi Syndrome (PWS).\n\nInvestors who purchased Soleno securities between March 26, 2025, and November 4, 2025, have until May 5, 2026, to seek appointment as lead plaintiff.","key_figures":{"drugName":"DCCR","phaseOfTrial":"Phase 3","customDimensions":{"class_period_end":"November 4, 2025","class_period_start":"March 26, 2025","lead_plaintiff_deadline":"May 5, 2026"}},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["DCCR"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO","relationship":"defendant"},{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T22:17:22.384Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.628Z"}},"durationMs":273483,"modelName":"glm-4.7"}}